For the targeted detection of somatic mutations in CTCs and tissue we used the iPLEX HS technology in conjunction with the MALDI-TOF based MassARRAY System (Agena Bioscience, San Diego, California). Here we used the Lung Panel covering 70 mutations in five key oncogenes (BRAF, EGFR, ERBB2, KRAS and PIK3CA) implicated in disease progression and therapy response. A mutation signal produced using iPLEX HS chemistry can be reliably detected by the MassARRAY System at about 1% VAF23 (link).
Free full text: Click here